What Is Monosomy 7 and Its Prognosis?

Monosomy 7 is the loss of one of the two copies of chromosome 7 in blood-forming cells, and it is one of the most common and most prognostically unfavorable chromosomal abnormalities found in myeloid blood cancers. It has been recognized as a hallmark of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) for roughly half a century, spanning every age group and arising from multiple causes.¹ The prognosis depends heavily on context, but the general picture is sobering: monosomy 7 signals aggressive disease, high relapse rates, and limited response to standard chemotherapy, though stem cell transplantation and emerging targeted treatments offer hope for some patients.

What Happens When a Cell Loses Chromosome 7

Every healthy human cell carries 23 pairs of chromosomes, for a total of 46. Monosomy 7 means that blood-forming stem cells in the bone marrow have lost one entire copy of chromosome 7, leaving them with only 45 chromosomes. A related abnormality, del(7q), involves the loss of just part of the long arm of chromosome 7 rather than the whole thing. Both are lumped together in clinical discussions because they share overlapping consequences, though full monosomy 7 generally carries a worse outlook than a partial deletion.²

This abnormality is not inherited in the usual sense. It arises in the bone marrow cells themselves, often after exposure to toxic chemicals, radiation, or prior chemotherapy, though it can also appear without any obvious trigger. The affected clone of cells then outcompetes normal blood-forming cells, gradually taking over production in the marrow. Because healthy blood cell production depends on proper signaling from chromosome 7’s genes, the result is a bone marrow that makes blood cells poorly, producing too few normal red cells, white cells, or platelets. That disordered production is the core of MDS, and it can progress to full-blown AML.

Why Losing Chromosome 7 Is So Dangerous

Chromosome 7 carries several genes that act as brakes on cancer or that help cells repair damaged DNA. Losing one copy means these genes are only working at half-strength, a concept called haploinsufficiency. Research has identified at least two key genes in the deleted regions: CUX1 and EZH2. When both are lost simultaneously, their combined absence drives clonal expansion of abnormal cells and makes those cells resistant to DNA-damaging chemotherapy.³ Studies in AML have confirmed that CUX1, EZH2, and another gene called MLL3 are consistently under-expressed in monosomy 7 cells.⁴

Mapping studies have shown that the deletions are not random. The most commonly lost stretch of the long arm spans a region around bands 7q22 through 7q36, with evidence for at least two or three distinct critical zones whose loss contributes to disease progression.⁵ One research group narrowed a frequently deleted segment to a roughly 4-to-5 million base-pair stretch in bands 7q35-q36.⁶ Earlier workshop data from dozens of patients found that when only part of 7q was missing, the segment from 7q32 to 7q34 was the most consistently deleted.⁷ The picture that emerges is of multiple tumor-suppressor genes scattered along 7q, each of which nudges marrow cells closer to malignancy when its dosage is halved.

Prognosis in Adults

Monosomy 7 places adult patients squarely in the adverse-risk category under current leukemia classification systems. The European LeukemiaNet (ELN) 2022 guidelines list monosomy 7 among the cytogenetic abnormalities that define adverse-risk AML.⁸ A Spanish registry study of 133 MDS patients with chromosome 7 problems found that those with isolated monosomy 7 fared considerably worse than those with just a partial deletion of 7q.² When monosomy 7 appeared alongside additional chromosomal abnormalities, outcomes were worse still.

How much worse? Data on MDS with monosomy 7 have shown relapse rates around 81% within the first year and event-free survival at seven years as low as 6%.⁹ Those numbers reflect the difficulty of controlling the disease with standard treatments. Prognosis worsens further when monosomy 7 coincides with mutations in TP53, a gene that normally protects cells from becoming cancerous. Patients with both an adverse-risk karyotype and TP53 mutations had a median overall survival of about eight months, compared to roughly 21 months for adverse-risk patients without TP53 mutations.⁸

The Mutational Landscape That Accompanies Monosomy 7

Monosomy 7 rarely acts alone. Analysis of the mutations co-occurring in MDS with monosomy 7 has found that nearly half of patients carry mutations in ASXL1, with about a third carrying SETBP1 mutations, and a similar proportion carrying U2AF1 mutations.¹⁰ Certain mutation pairs turn up together more often than chance would predict, including combinations of U2AF1 with ETV6 and SETBP1 with U2AF1. These co-mutations shape the disease’s behavior and can affect how well a patient responds to specific treatments, which is why molecular profiling has become a routine part of the diagnostic workup for anyone found to have monosomy 7.

Prognosis in Children

Monosomy 7 in children overlaps with adult disease but also has some distinctive features. In pediatric MDS, monosomy 7 is one of the most frequent chromosomal abnormalities and plays a central role in disease progression. Among 20 children with the low-grade MDS subtype called refractory cytopenia of childhood (RCC) who had monosomy 7, the median time to progression was about 1.7 years, faster than for children with other cytogenetic abnormalities or normal karyotypes.¹¹

However, the outlook after stem cell transplant is more encouraging in children than the raw relapse figures might suggest. A study of 100 children with MDS and monosomy 7 who underwent transplant reported five-year event-free and overall survival rates of about 66% and 69%, respectively.¹¹ Those numbers reflect how aggressive treatment with transplant can meaningfully change the trajectory, even in a disease typically called adverse-risk. In juvenile myelomonocytic leukemia (JMML), a childhood blood cancer where monosomy 7 also occurs, one prospective study of 90 children found that the presence of monosomy 7 did not worsen outcomes beyond what was already expected for the disease itself.¹²

Inherited Conditions That Lead to Monosomy 7

Some children develop monosomy 7 not by random bad luck but because they carry inherited mutations that predispose their bone marrow to lose chromosome 7. Two genetic syndromes are the most common culprits: GATA2 deficiency and SAMD9/SAMD9L syndromes. Together, these account for the majority of primary pediatric MDS cases that present with monosomy 7.¹³

In one consecutively diagnosed MDS cohort, germline SAMD9/SAMD9L mutations accounted for about 8% of cases and GATA2 mutations for about 7%. Among the SAMD9/SAMD9L group, monosomy 7 was present in roughly 38%, and over half had constitutional abnormalities affecting other organ systems, including immune dysfunction in about 28%.¹⁴ The SAMD9 and SAMD9L genes both sit on chromosome 7 itself, which creates a strange feedback loop: the germline mutation suppresses cell growth, and the bone marrow “escapes” by discarding the chromosome carrying the harmful mutation. That escape mechanism is monosomy 7, but it comes at the cost of losing all the tumor-suppressor genes on that chromosome.

Transient Monosomy 7 in Young Children

One of the more surprising findings in recent years is that monosomy 7 can sometimes disappear on its own in very young children with SAMD9L syndrome. In a study tracking children with SAMD9L mutations and monosomy 7, three experienced spontaneous blood count recovery within 14 months, with the monosomy 7 clone shrinking dramatically.¹⁵ The mechanism behind this involves a form of self-correction: the marrow develops subclones that acquire a second mutation neutralizing the harmful germline SAMD9L variant, allowing healthy blood production to resume without the monosomy 7 clone.

Long-term follow-up of families with SAMD9L mutations has shown a range of outcomes: some patients progress to leukemia, some maintain persistent monosomy 7, and others experience transient monosomy 7 followed by spontaneous recovery.¹⁶ The most common forms of somatic genetic rescue in these patients include monosomy 7 itself, secondary loss-of-function mutations that disable the problematic SAMD9L copy, or a process called uniparental disomy of 7q, where the cell replaces the mutant chromosome segment with a duplicate of the healthy one.¹⁷ The possibility of spontaneous resolution makes clinical decisions tricky: transplanting too early may be unnecessary, but waiting too long risks progression to AML.

How Monosomy 7 Is Detected

Standard chromosome analysis (karyotyping) of a bone marrow sample is typically the first step, but it does not catch every case. In one report, a child’s standard karyotype from peripheral blood came back normal, but chromosomal microarray testing detected over 20% mosaicism for monosomy 7, leading to a presymptomatic diagnosis of MDS and early treatment with transplant.¹⁸ That case illustrates why relying on a single test can be misleading, especially when the abnormal clone is small.

A comparative study using karyotyping, FISH (fluorescence in situ hybridization), and SNP array testing on patients with MDS found that no single method detected all chromosome 7 abnormalities. Detection rates improved when all three methods were used together.¹⁹ SNP arrays have the added advantage of detecting uniparental disomy, which neither karyotyping nor FISH can identify. For children known to carry germline SAMD9/SAMD9L or GATA2 mutations, this level of testing detail matters for distinguishing between true monosomy 7, partial deletions, and self-correcting clonal dynamics.

Treatment and Transplant Outcomes

Allogeneic stem cell transplant remains the only curative option for most patients with monosomy 7 MDS. A European registry study of 277 adults with chromosome 7 abnormalities who underwent transplant reported five-year progression-free survival of 22% and overall survival of 28%. Patients who entered transplant with more advanced disease stages or whose karyotypes included additional monosomies (a pattern called monosomal karyotype) fared worse.²⁰ These numbers underscore why early detection and referral for transplant evaluation are emphasized.

For patients who cannot undergo transplant, or who need a bridge to transplant, hypomethylating agents like decitabine are sometimes used. A subgroup analysis from a randomized trial found that decitabine improved progression-free survival in high-risk MDS patients whose karyotypes included two or more autosomal monosomies, with an overall response rate of about 44% in that group. However, overall survival was not significantly improved in any subgroup.²¹ The honest takeaway is that non-transplant treatments can buy time and reduce symptoms, but they rarely lead to long-term disease control on their own.

Surveillance for Children With Known Predisposition

For families where a germline predisposition has been identified, ongoing surveillance is recommended. Current guidelines call for regular complete blood counts and periodic bone marrow evaluations in children at risk for MDS, with the goal of catching presymptomatic changes before full-blown disease develops.²² A specialized review is particularly important because some morphologic changes in the bone marrow can look abnormal even at baseline in children with hereditary predisposition, without actually indicating MDS. Persistent symptoms or changes in blood counts should prompt more frequent follow-up.

The surveillance challenge is real for families. These are children who may appear perfectly healthy but require regular blood draws and occasional bone marrow biopsies to monitor for a disease that may or may not materialize. For children with SAMD9L syndromes specifically, the possibility of spontaneous resolution adds another layer of complexity: an initially alarming finding of monosomy 7 may, in a young child, resolve on its own without treatment.

Emerging Targeted Therapies

There are currently no approved drugs that specifically target monosomy 7, but early research has identified vulnerabilities worth pursuing. One discovery involves a gene called NAMPT, located at 7q22.3. Because one copy of NAMPT is lost in monosomy 7 cells, those cells produce less of the enzyme than normal cells do. Researchers found that monosomy 7 AML cells were highly sensitive to drugs that inhibit the remaining NAMPT activity, essentially exploiting the tumor’s own weakness.²³ NAMPT inhibitors are already in clinical development for other cancers, so the pathway to testing them in monosomy 7 patients is relatively straightforward.

Another avenue involves cases where monosomy 7 AML harbors hidden ALK gene fusions. ALK fusions are better known in lung cancer, where they are successfully targeted with drugs like crizotinib. Researchers identified similar fusions in some monosomy 7 AML cases and found that crizotinib showed activity against those cells in laboratory testing.²⁴ Neither of these approaches has yet reached large clinical trials, but they represent a shift in thinking: rather than treating monosomy 7 as a uniformly intractable problem, researchers are learning to pick apart its specific molecular weaknesses and attack them individually.

Mosaicism and Unusual Presentations

Monosomy 7 does not always present in a straightforward way. Some patients have mosaic monosomy 7, meaning only a fraction of their marrow cells carry the abnormality while the rest have normal chromosomes. This can make diagnosis harder, as the abnormal clone may be too small to detect with standard karyotyping alone. In rare constitutional cases, monosomy 7 can coexist with a ring chromosome 7, where the chromosome forms a circular structure instead of the normal linear one. One case report described a child with three different cell lines in blood and tissue samples: cells with ring chromosome 7, cells with monosomy 7, and cells with a duplicated ring chromosome.²⁵ These unusual configurations are rare, but they remind clinicians that what looks like a simple chromosome count can conceal more complicated biology underneath.

The distinction between constitutional monosomy 7 (present in all cells from birth, extremely rare and usually lethal) and acquired monosomy 7 (arising in blood-forming cells later in life) matters clinically. The acquired form is what most oncologists are dealing with, and even within that group, the size of the monosomy 7 clone, the presence of additional mutations, and the patient’s underlying genetic predisposition all feed into the prognosis. Two patients with the same cytogenetic label of “monosomy 7” can have markedly different outcomes depending on these variables.

1
PubMed. The enigma of monosomy 7
2
Wiley Online Library / PubMed Central. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome
3
Blood Neoplasia. Multiplex gene editing models of del(7q) reveal combined CUX1 and EZH2 loss drives clonal expansion and drug resistance
4
Cancer Research. Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality
5
PubMed. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases
6
PubMed. Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders
7
PubMed. Fourth International Workshop on Chromosomes in Leukemia 1982: Abnormalities of chromosome 7 resulting in monosomy 7 or in deletion of the long arm (7q-)
8
PubMed Central. Proposed Refinement of 2022 European LeukemiaNet Adverse-Risk Group of AML Patients Using a Real-World Cohort
9
IntechOpen. Myelodysplastic Disorders, Monosomy 7 – Section: 7. Monosomy 7 MDS
10
PubMed. Mutational Pattern and Clonal Hierarchy in MDS with Monosomy 7
11
Haematologica. Germline and somatic genetic landscape of pediatric myelodysplastic syndromes – Section: Central role of monosomy 7 in the evolution of pediatric myelodysplastic syndromes
12
PubMed. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome
13
PubMed Central. Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes
14
Nature Medicine. Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
15
PubMed Central. Spontaneous remission and loss of monosomy 7: a window of opportunity for young children with SAMD9L syndrome
16
PubMed Central. Constitutional SAMD9L mutations cause familial myelodysplastic syndrome and transient monosomy 7
17
PubMed Central. From a novel pathogenic SAMD9L variant to cohort-wide insights: Whole-genome sequencing highlights somatic genetic rescue and phenotypic heterogeneity
18
PubMed Central. Clinical utility of chromosomal microarray analysis in the diagnosis and management of monosomy 7 mosaicism
19
PubMed Central. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q)
20
Leukemia. Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia
21
PubMed. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies
22
Clinical Cancer Research. Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy
23
PubMed Central. Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia
24
PubMed. Functional consequence and therapeutic targeting of cryptic ALK fusions in monosomy 7 acute myeloid leukemia
25
PubMed. Cytogenomic and phenotypic analysis in low-level monosomy 7 mosaicism with non-supernumerary ring chromosome 7